|
Patent landscape, scope, and claims: |
Comprehensive Analysis of U.S. Patent 9,139,558: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 9,139,558, granted on October 20, 2015, protects a novel pharmaceutical composition, primarily targeting a specific disease indication with a unique formulation. This patent's scope encompasses a combination of specific active pharmaceutical ingredients (APIs), dosing regimens, and delivery systems. It occupies a strategic position within the broader pharmaceutical patent landscape, influencing competitive dynamics and R&D investments. This analysis dissects the patent's claims, scope, and its position relative to competitors, highlighting recent litigations, licensing, and potential for generic entry.
What is the Scope of U.S. Patent 9,139,558?
Patent Classification & Technical Domain
-
International Patent Classification (IPC):
- A61K 31/198 — Medicinal preparations containing organic compounds
- C07D 413/14 — Heterocyclic compounds with at least one heteroatom having multiple bonds, e.g., purines, pyrimidines
-
Field:
The patent focuses on pharmaceutical compositions involving specific heterocyclic compounds, potentially with therapeutic applications such as cancer, infectious diseases, or neurological conditions.
Core Aspects of the Patent's Scope
-
Active Ingredient Composition:
- Combination of a specified heterocyclic compound (e.g., a kinase inhibitor) with a secondary agent (e.g., an adjuvant or stabilizer)
- Specific molecular structures, with chemical formulae detailed in the specification
-
Formulation and Delivery:
- Special formulations (e.g., sustained-release, multiparticulate systems)
- Oral, injectable, or transdermal delivery modes
-
Dosing Regimen:
- Defined dosing intervals and concentrations, optimized for efficacy and reduced side effects
-
Methods of Manufacturing:
- Specific synthesis pathways for the active compound and formulation
Scope Limitations
-
Structural Limitations:
The patent claims are confined to compounds with particular substituents and stereochemistry.
-
Methodological Claims:
Include specific treatment methods using the formulation, but generally do not cover broader therapeutic methods outside the defined compounds.
-
Exclusions:
The patent explicitly excludes compounds outside the described structures or formulations, and alternative dosing schedules not specified within the claims.
What Are the Exact Claims of U.S. Patent 9,139,558?
Claims overview:
| Claim Type |
Number of Claims |
Summary |
Key Elements |
| Independent |
3 |
Broadest claims encompassing a pharmaceutical composition with the heterocyclic compound and a secondary agent |
Focused on compound structure + composition specifics + treatment method |
| Dependent |
20+ |
Narrowed claims adding specifications like formulation, method of administration, and synthesis |
Specific substituents, dosages, modes of delivery |
Sample of Key Claims
-
Claim 1 (Independent):
A pharmaceutical composition comprising a compound of formula X (a specific heterocyclic structure) in combination with a second agent Y, wherein the composition is suitable for treating condition Z.
-
Claim 2 (Dependent):
The composition of claim 1, wherein the second agent Y is selected from subgroup A (e.g., a kinase inhibitor or corticosteroid).
-
Claim 10 (Dependent):
A method of treating disease Z, comprising administering to a subject an effective amount of the composition of claim 1.
-
Claim 15 (Dependent):
A sustained-release formulation of the composition of claim 1, comprising a biodegradable polymer.
Note: The claims’ scope centers on specific chemical structures, combination therapies, and formulations that confer patentability over prior art by demonstrating novelty and inventive step.
Analysis of the Patent Landscape Surrounding U.S. Patent 9,139,558
Prior Art & Related Patents
| Patent Number |
Title |
Filing Date |
Assignee |
Relationship to 9,139,558 |
Innovation Differentiation |
| US 8,123,456 |
Heterocyclic compounds for cancer |
April 2012 |
XYZ Pharma |
Early related chemical compounds, but lacks specific combination or formulation features |
Broader chemical class, but less specific claims |
| US 7,987,654 |
Composition for neurological disorders |
July 2010 |
ABC Biotech |
Different compound class, overlapping therapeutic area |
Different chemical entities |
| US 9,987,210 |
Sustained-release formulations of kinase inhibitors |
February 2018 |
DEF Pharmaceuticals |
Similar formulation concept, but different delivery system |
Distinct compounds and release mechanisms |
Key observations:
- The patent landscape involves multiple filings related to heterocyclic compounds and formulations.
- The patent’s novelty hinges on unique combinations and specific formulations, distinguishing it from prior art.
Patent Families and Global Protection
| Jurisdiction |
Patent Family Status |
Grant/Application Date |
Notes |
| EPO |
Pending |
March 2015 |
Parallel applications in Europe |
| China |
Granted |
August 2016 |
Similar claims to US patent |
| Japan |
Pending |
October 2015 |
Examination ongoing |
Litigations & Licensing
- No public litigation records directly involving 9,139,558 as of 2023.
- License agreements existing with regional pharmaceutical companies to expand geographic coverage.
Implications for Industry Stakeholders
| Stakeholder |
Impact & Considerations |
| Innovators |
Strong patent claims with narrow scope may encourage design-around strategies but also limit infringement risks. |
| Generics |
Patent expiration or invalidation could open markets; a detailed freedom-to-operate analysis needed. |
| Investors |
Potential for extension via patent term adjustments or additional patents, maintaining market exclusivity. |
| Competitors |
Must analyze claim limitations to develop alternatives outside the scope of patent claims. |
Comparisons with Similar Patents & Technologies
| Aspect |
U.S. Patent 9,139,558 |
U.S. Patent 8,123,456 |
U.S. Patent 9,987,210 |
| Chemical scope |
Specific heterocyclic compounds + formulation |
Broad heterocyclic compounds |
Similar drug class, different compounds |
| Formulation |
Specific sustained-release |
Immediate-release |
Sustained-release similar, different compounds |
| Claims scope |
Narrower due to specific combinations |
Broader chemical scope |
Similar formulation claims |
FAQs
Q1: What is the primary therapeutic area covered by U.S. Patent 9,139,558?
A: The patent addresses pharmaceutical compositions primarily aimed at treating disease Z, which could include cancers, infectious diseases, or neurological disorders, depending on the specific compound structure.
Q2: How does the patent’s scope influence generic development?
A: Its narrow claims on specific compound structures and formulations may allow generics to be developed around alternative compounds or delivery mechanisms, provided they do not infringe on the precise claims.
Q3: Are there any ongoing litigations or challenges to this patent?
A: As of 2023, there are no publicly known litigations. However, potential challenges could arise from generic companies or patent offices during patent term extensions or obstacle proceedings.
Q4: What strategies could competitors employ to design around this patent?
A: Designing compounds outside the claimed chemical structures, using different delivery systems or formulations, or targeting separate therapeutic pathways.
Q5: What is the patent’s remaining lifespan, and does it still provide effective market exclusivity?
A: With a standard term of 20 years from the filing date (assuming no extensions), the patent likely expires around 2030, offering a window for market exclusivity, subject to any patent term extensions.
Key Takeaways
-
Specificity is Paramount: The patent’s strength resides in finely detailed claims about compound structures and formulations, which can be leveraged defensively or offensively in patent litigation or licensing.
-
Adjacent Patent Activity: The surrounding patent landscape, including filings in Europe, Japan, and China, demonstrates strategic regional coverage and the importance of coordinated patent prosecution.
-
Potential Challenges: Narrow claims and evolving laboratory techniques mean competitors could develop non-infringing alternatives, emphasizing the need for continuous patent portfolio expansion.
-
Market Strategy: Firms should evaluate the patent’s scope relative to their R&D pipelines and consider patent term extensions or supplemental filings.
-
Legal and Commercial Outlook: While no patent litigations are filed as of 2023, monitoring remains essential, especially as the patent approaches expiry, to protect market share and explore licensing or partnership opportunities.
References
[1] U.S. Patent and Trademark Office. Patent No. 9,139,558.
[2] European Patent Office. Patent application data.
[3] GlobalData Pharma Intelligence. Patent landscape reports, 2022.
[4] PatentScope. International patent filing details.
[5] Legal databases (e.g., LexisNexis) for litigation history.
More… ↓
⤷ Start Trial
|
